Zepbound vials were introduced in late August 2024 in an effort to increase supply of and accessibility to the medication
Patients should check with their insurance provider to see if either drug is included in their plan
For now, we will have to take it by injection once a week
These dual GIP/GLP-1 receptor agonists, administered weekly for type 2 diabetes and weight management, cause injection site reactions in approximately 2-5% of patients
GLP-Squared Injection (semaglutide plus tirzepatide, $289/month) combines two mechanisms and may offer superior weight loss for post-cholecystectomy patients who tolerate dual therapy, though it intensifies GI effects
By addressing lifestyle factors, giving the medication time to work, and consulting with your healthcare provider, you can optimize your weight loss journey